<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03967652</url>
  </required_header>
  <id_info>
    <org_study_id>NanoBreathDiag</org_study_id>
    <nct_id>NCT03967652</nct_id>
  </id_info>
  <brief_title>Cancer Diagnoses From Exhaled Breath With Na-nose</brief_title>
  <official_title>Diagnosing Cancers From Healthy From Human Exhaled Breath With Na-nose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technion, Israel Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Anhui Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early diagnoses of malignant tumors are pivotal for improving their prognoses. The Exhaled
      Breath is made up of oxygen, carbon dioxide, nitrogen, water, inert gases and volatile
      organic compounds (VOCs). Theoretically, the concentration of VOCs in exhalation produced by
      metabolism in human body is only about nmol/L-pmol/L, which can significantly increase under
      certain pathological conditions. A series of studies of VOCs diagnosing solid tumors the
      investigators had been conducted in the past decade. It was found that VOCs in exhaled breath
      can not only distinguish different types of tumors, but also can make a clear distinction
      between different stages. Our long-term collaborator, Professor Hossam Haick (Israel
      Institute of Technology) has developed a nano sensor array, so called Na-nose, which can
      detect VOCs of the exhaled breath by binding gases to specific chemiresistors coated with
      gold nanomaterials. The Na-nose has the advantages of low cost, easy to use, good
      reproducibility and real-time detection for large scale clinical application. This study was
      to use large clinical samples to validate the diagnostic efficacy of the newly developed
      Nano-nose( Sniffphone and Breath Screener) for malignant tumors .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Israel Institute of Technology provides two type of Na-nose. One is Breath Screener used for
      large-scale sampling and feature VOCs extraction to establish database. The other is called
      Sniff Phone aim at clinical real-time VOCs detection assisted by software. About 10,000
      patients will participate in the subject of Breath Screener in batches. First, 7000 patients
      will have a definitive diagnosis and exhaled breath collected. Feature VOCs of specific
      tumors will be extracted from these samples and employed to build predictive model by using
      discriminant factor analysis (DFA). After the predictive model had been completed, 3000
      definitively diagnosed patients will participate in validating the specificity and
      sensitivity of the prediction model. With the assistance of Breath Screener clinical database
      and software services, Sniff Phone is more suitable for clinical real-time detection for its
      small and convenient design characteristics. At last, Breath Screener and Sniff Phone will
      continue enriching databases and improve diagnosis efficacy in their clinical applications.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Build predictive diagnosis database</measure>
    <time_frame>From July 01,2019 to December 31,2021</time_frame>
    <description>First, feature VOCs of specific tumors will be extracted from part of collected samples and employed to build predictive model. After the predictive model had been completed, number of definitively diagnosed patients will participate in validating the specificity and sensitivity of the prediction model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Associated feature exhaled breath with differentially expressed genes</measure>
    <time_frame>From Juan 01,2022 to December 31,2022</time_frame>
    <description>Integrate the correlation and relevance between the exhaled samples and the differentially expressed genes in the cancer group and the benign / normal control group to explore the mechanism of feature VOCs' production.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Volatile Organic Compounds</condition>
  <condition>Cancer</condition>
  <condition>Diagnoses Disease</condition>
  <arm_group>
    <arm_group_label>cancer</arm_group_label>
    <description>Patients with definitively diagnosed of solid tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benign disease</arm_group_label>
    <description>Patients with definitively diagnosed of benign disease or precancerous lesion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal</arm_group_label>
    <description>Healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Nanomaterial-based sensors</intervention_name>
    <description>Chemical sensors based on Monolayer-Capped Metallic Nanoparticles (MCMNPs) can recognize and classify exhaled breath by special recognition algorithm, which achieves the purpose of disease diagnosis.</description>
    <arm_group_label>Benign disease</arm_group_label>
    <arm_group_label>Normal</arm_group_label>
    <arm_group_label>cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        10,000 volunteers who had a definitively diagnosis with surgery or endoscope
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-75 years

          -  Cancer/benign disease having been diagnosed by pathology

          -  ECOG &lt; 2

        Exclusion Criteria:

          -  Concomitant malignancies other than one malignant tumor

          -  Diabetes, Fatty liver

          -  Autoimmune disease

          -  Ventilation and transaired function obstacle
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hu Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anhui Provincial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bao Chuyang, MD</last_name>
    <phone>+86 18555039598</phone>
    <email>des_mond@outlook.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hu Liu, MD</last_name>
    <phone>+86 13866175691</phone>
    <email>drliuhu@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Nakhleh MK, Amal H, Jeries R, Broza YY, Aboud M, Gharra A, Ivgi H, Khatib S, Badarneh S, Har-Shai L, Glass-Marmor L, Lejbkowicz I, Miller A, Badarny S, Winer R, Finberg J, Cohen-Kaminsky S, Perros F, Montani D, Girerd B, Garcia G, Simonneau G, Nakhoul F, Baram S, Salim R, Hakim M, Gruber M, Ronen O, Marshak T, Doweck I, Nativ O, Bahouth Z, Shi DY, Zhang W, Hua QL, Pan YY, Tao L, Liu H, Karban A, Koifman E, Rainis T, Skapars R, Sivins A, Ancans G, Liepniece-Karele I, Kikuste I, Lasina I, Tolmanis I, Johnson D, Millstone SZ, Fulton J, Wells JW, Wilf LH, Humbert M, Leja M, Peled N, Haick H. Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules. ACS Nano. 2017 Jan 24;11(1):112-125. doi: 10.1021/acsnano.6b04930. Epub 2016 Dec 21.</citation>
    <PMID>28000444</PMID>
  </reference>
  <reference>
    <citation>Barash O, Zhang W, Halpern JM, Hua QL, Pan YY, Kayal H, Khoury K, Liu H, Davies MP, Haick H. Differentiation between genetic mutations of breast cancer by breath volatolomics. Oncotarget. 2015 Dec 29;6(42):44864-76. doi: 10.18632/oncotarget.6269.</citation>
    <PMID>26540569</PMID>
  </reference>
  <reference>
    <citation>Amal H, Shi DY, Ionescu R, Zhang W, Hua QL, Pan YY, Tao L, Liu H, Haick H. Assessment of ovarian cancer conditions from exhaled breath. Int J Cancer. 2015 Mar 15;136(6):E614-22. doi: 10.1002/ijc.29166. Epub 2014 Sep 5.</citation>
    <PMID>25159530</PMID>
  </reference>
  <reference>
    <citation>Amal H, Leja M, Broza YY, Tisch U, Funka K, Liepniece-Karele I, Skapars R, Xu ZQ, Liu H, Haick H. Geographical variation in the exhaled volatile organic compounds. J Breath Res. 2013 Dec;7(4):047102. doi: 10.1088/1752-7155/7/4/047102. Epub 2013 Nov 1.</citation>
    <PMID>24184568</PMID>
  </reference>
  <reference>
    <citation>Leja MA, Liu H, Haick H. Breath testing: the future for digestive cancer detection. Expert Rev Gastroenterol Hepatol. 2013 Jul;7(5):389-91. doi: 10.1586/17474124.2013.811033.</citation>
    <PMID>23899275</PMID>
  </reference>
  <reference>
    <citation>Amal H, Ding L, Liu BB, Tisch U, Xu ZQ, Shi DY, Zhao Y, Chen J, Sun RX, Liu H, Ye SL, Tang ZY, Haick H. The scent fingerprint of hepatocarcinoma: in-vitro metastasis prediction with volatile organic compounds (VOCs). Int J Nanomedicine. 2012;7:4135-46. doi: 10.2147/IJN.S32680. Epub 2012 Jul 30.</citation>
    <PMID>22888249</PMID>
  </reference>
  <reference>
    <citation>Xu ZQ, Broza YY, Ionsecu R, Tisch U, Ding L, Liu H, Song Q, Pan YY, Xiong FX, Gu KS, Sun GP, Chen ZD, Leja M, Haick H. A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditions. Br J Cancer. 2013 Mar 5;108(4):941-50. doi: 10.1038/bjc.2013.44.</citation>
    <PMID>23462808</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>May 29, 2019</last_update_submitted>
  <last_update_submitted_qc>May 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Anhui Provincial Hospital</investigator_affiliation>
    <investigator_full_name>Hu Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Volatile organic chemicals</keyword>
  <keyword>Cancer</keyword>
  <keyword>Diagnose Disease</keyword>
  <keyword>Na-nose</keyword>
  <keyword>breath diagnoses</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

